Neurolief develops proprietary digital theraputics neuromodulation technology to treat neurological and neuropsychiatric disorders such as migraine and depression. The company’s devices either complement or provide an alternative to pharmaceutical therapies, which are often ineffective and are associated with potential short- and long-term adverse effects. Neurolief’s products are groundbreaking electronic head mounted devices designed to concurrently neuromodulate target major neural pathways in the head and thereby affect brain regions that are involved in control and modulation of pain and mood. These devices are intended to provide a highly effective, side-effects free treatment for the hundreds of millions of patients worldwide.
Neurolief is led by a seasoned team with extensive experience and successful track record developing multiple neuromodulation devices for patients with central nervous system deficiencies.
Neurolief is led by a seasoned team with extensive experience and successful track record developing multiple neuromodulation devices for patients with central nervous system deficiencies.
Location: United States
Employees: 11-50
Total raised: $6M
Founded date: 2013
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.03.2026 | - | $6M | - |
Mentions in press and media 9
| Date | Title | Description |
| 31.03.2026 | Neurolief Secures Major Funding for At-Home Depression Therapy | Neurolief secures $6M from BrainsWay. FDA approved its ProlivRx system. This brain neuromodulation therapy treats major depressive disorder at home. It targets patients resistant to antidepressants. The investment fuels U.S. rollout. It vas... |
| 30.03.2026 | Neurolief Raises Additional $6M Investment | Neurolief Proliv Rx Neurolief, a Coral Springs, FL-based medical technology company developing neuromodulation therapies for mental health conditions, raised a $6M investment from BrainsWay Ltd. The news followed the FDA Premarket Approval ... |
| 30.03.2026 | Neurolief: $6 Million Investment Raised For FDA-Approved At-Home Depression Neuromodulation Therapy | Neurolief, a neuroscience-driven medical technology company focused on non-invasive neuromodulation therapies, has secured a $6 million milestone-based investment from BrainsWay following FDA Premarket Approval of its ProlivRx system. The f... |
| 13.12.2022 | Neurolief Appoints Neuromodulation Industry Leader Scott Drees as CEO | As a 27-year pioneer in neuromodulation, Scott is a proven leader, whose experience in neuromodulation positions him to take Neurolief to its next phase of growth.” — Raphael Ben Dror, Neurolief Chairman of the Board TAMPA, FL, UNITED STATE... |
| 29.06.2022 | Neurolief Announces Publication of the RIME Pivotal Study for Relivion MG – a Digital Therapeutics Platform for Migraine | Results of clinical study demonstrate non-invasive combined occipital and trigeminal neuromodulation system may offer pronounced benefit for migraine patients. TAMPA, FL, UNITED STATES, June 29, 2022 /EINPresswire.com/ -- Neurolief, a neuro... |
| 14.06.2022 | New Data Demonstrates Substantial Reduction of Migraine Days Using Neurolief’s Digital Therapeutics Technology | 85% of patients achieved at least a 50% reduction in monthly migraine days using the eCOT-NS technology system, according to real-world, open-label analysis TAMPA, FL, USA, June 14, 2022 /EINPresswire.com/ -- Neurolief, a neurotechnology in... |
| 09.06.2022 | Neurolief’s Digital Therapeutics Neuromodulation System May Challenge Medication Therapies for the Treatment of Migraine | Study shows 76% of patients treated with Relivion achieved headache pain relief at 2 hours TAMPA, FL, USA, June 9, 2022 /EINPresswire.com/ -- Neurolief, a neurotechnology innovator, today announces the publication of the SP301 study in the ... |
| - | Neurolief | - |
| - | Neurolief | “Neurolief is a leader in brain neuromodulation, committed to providing relief for millions suffering from mental health and neurological disorders.” |